Tests clot-dissolving drug delivered into arteries for ischemic stroke from medium vessel blockage
Tests clot-dissolving drug given into an artery in adults with stroke.
Plain-language title generated from the registry record
Registry title: Intra-arterial Thrombolysis for Acute Ischemic Stroke With Medium Vessel Occlusion
Key facts
- Where
- Fuyang, Hefei, Lishui, Liuzhou, and Lu'an, ChinaSee the 6 sites
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with an acute stroke caused by a blocked medium-sized brain artery or a severely narrowed one. It tests a clot-dissolving drug given into the artery.
- Age
- Older than 18 years
- Sex
- All sexes can join.
- Disease stage
- Acute ischemic stroke from a blocked medium vessel or severe narrowing (70% or more) of a brain artery, seen on CTA, MRA, or DSA. Stroke score (NIHSS) 5 to 25, or 3 to 4 if there are disabling problems such as vision loss, speech problems, or weakness. Treatment must start within 24 hours of onset or last known well, or within 24 to 72 hours if scans meet set criteria.
- Biomarker or test result
- For the 24 to 72 hour window, scans must show a target mismatch or a DWI-FLAIR mismatch, as set out in the record. For the first 24 hours, CT must show no obvious dark area and CTA must show good collateral blood flow.
Main reasons for not taking part
- Disability before the stroke (mRS 2 or higher)
- Bleeding in the brain on scans, or brain bleeding in the past 3 months
- A clearly dark area on CT in the affected artery's territory
- Bleeding tendency, platelets below 100 × 10⁹/L, or INR above 3.0
- Blood pressure that stays too high: above 185 (systolic) or 110 (diastolic) mmHg
Read by machine on 12 November 2026.
Where in China
- Fu Yang People's HospitalFuyang, ChinaContact: Juluo ChenTaking people
- Lin Quan People's HospitalFuyang, ChinaContact: Susheng LongTaking people
- The Second Affiliated Hospital Of Anhui Medical UniversityHefei, ChinaContact: Qi Li, professorTaking people
- Lishui Central HospitalLishui, ChinaContact: Xiao PengTaking people
- Liuzhou Worker's HospitalLiuzhou, ChinaContact: Xianfu LuTaking people
- Shucheng People's HospitalLu'an, ChinaContact: Jianshang WenTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- The Second Hospital of Anhui Medical University
- Trial code
- NCT07185022
- Record updated
- 16 April 2026
- Original description
Acute ischemic stroke (AIS) due to medium vessel occlusion (MeVO) or severe stenosis poses a significant clinical challenge. Recent large randomized controlled trials, DISTAL and ESCAPE-MeVO, demonstrated no significant benefit of endovascular therapy in patients with MeVO. Although intra-arterial thrombolysis has shown promise in clinical experience, robust evidence supporting its efficacy in MeVO or severe stenosis-related AIS is still absent. To fill this gap, the RESCUE MeVO trial has been designed as a multicenter, prospective, randomized, open-label, blinded end-point (PROBE) study to evaluate the efficacy and safety of intra-arterial thrombolysis in patients with AIS caused by MeVO or severe stenosis.Read full original descriptionShow less
a Multicenter Prospective Randomized Controlled Trial of Intra-artErial thrombolysiS for aCUte Ischemic strokE With Medium Vessel Occlusion (RESCUE MeVO)
Acute ischemic stroke (AIS) due to medium vessel occlusion (MeVO) or severe stenosis poses a significant clinical challenge. Recent large randomized controlled trials, DISTAL and ESCAPE-MeVO, demonstrated no significant benefit of endovascular therapy in patients with MeVO. Although intra-arterial thrombolysis has shown promise in clinical experience, robust evidence supporting its efficacy in MeVO or severe stenosis-related AIS is still absent. To fill this gap, the RESCUE MeVO trial has been designed as a multicenter, prospective, randomized, open-label, blinded end-point (PROBE) study to evaluate the efficacy and safety of intra-arterial thrombolysis in patients with AIS caused by MeVO or severe stenosis.
Inclusion: Age > 18 years; Primary medium vessel occlusion (MeVO) or severe stenosis (≥70%) was detected on CTA, MRA, or DSA, involving arterial segments including M2-M3 of the middle cerebral artery (MCA), A1-A2 of the anterior cerebral artery (ACA), P1-P2 of the posterior cerebral artery (PCA), and the anterior inferior cerebellar artery (AICA), posterior inferior cerebellar artery (PICA), and superior cerebellar artery (SCA); The clinical symptoms were consistent with MeVO, with a NIHSS score 5 - 25, or an NIHSS score of 3-4 in the presence of disabling neurological deficits (e.g., hemianopia, aphasia, or motor dysfunction); Intra-arterial thrombolysis was administered within the following time windows:; Acute ischemic stroke within 24 hours of symptom onset or last known well, including stroke with known onset, wake-up stroke and stroke with unknown onset, with no obvious hypodensity on CT and good collateral circulation on CTA; Acute ischemic stroke within 24-72 hours of onset, meeting at least one of the following imaging criteria: a.CT or MR perfusion imaging demonstrating target mismatch, defined as an ischemic core volume <30 mL, a mismatch ratio ≥1.2, and a mismatch volume ≥10 mL.; b.MRI demonstrating DWI-FLAIR mismatch, defined as the presence of acute ischemic lesions on diffusion-weighted imaging (DWI) with no corresponding hyperintense signal on FLAIR, or with FLAIR hyperintense lesions occupying less than one-third of the DWI lesion volume; Signed informed consent obtained.
Exclusion: Secondary MeVO or severe stenosis caused by endovascular therapy; Pre-stroke mRS ≥ 2; Neuroimaging demonstrated intracranial hemorrhage, subarachnoid hemorrhage, or other hemorrhagic disorders; Persistent and uncontrolled hypertension, defined as systolic blood pressure >185 mmHg or diastolic blood pressure >110 mmHg; History of intracranial hemorrhage within the past 3 months, including parenchymal hemorrhage, intraventricular hemorrhage, subarachnoid hemorrhage, epidural hemorrhage, or subdural hemorrhage; Gastrointestinal or urinary tract bleeding, or major surgery within the past 3 months; Patients with known allergy to thrombolytic agents or their excipients; Patients with known allergy to iodinated contrast agents or other established contraindications; Platelet count <100 × 10⁹/L, known bleeding tendency or coagulation factor deficiency, or oral anticoagulant therapy with an international normalized ratio (INR) >3.0; Chronic dialysis or severe renal impairment, defined as a glomerular filtration rate (GFR) <30 mL/min or serum creatinine >220 μmol/L (2.5 mg/dL); Non-contrast CT demonstrating a clearly hypodense lesion corresponding to the vascular territory; Presence of arteriovenous malformations or brain tumors with mass effect; Pregnant or current breastfeeding; Presence of severe systemic comorbidities with a life expectancy of less than 3 months; Deemed unsuitable for participation by the investigator for any reason.